ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced treatment with ANKTIVA® (nogapendekin alfa inbakicept-pmln) plus Bacillus Calmette-Guérin (BCG) demonstrates efficacy ...
Stocktwits on MSN
IBRX gains 30% on fresh approval for bladder cancer drug in EU: Retail, Wall Street eyes further rally
ImmunityBio will submit long-term safety and efficacy data to the European Medicines Agency as part of the conditional ...
Zacks Investment Research on MSN
ImmunityBio wins EU nod for bladder cancer combo therapy, stock up
Shares of ImmunityBio, Inc. IBRX soared 41.9% on Wednesday after the company announced that the European Commission (EC) has granted conditional marketing authorization for Anktiva (nogapendekin alfa ...
Please provide your email address to receive an email when new articles are posted on . Patients with high-risk non-muscle-invasive bladder cancer who received durvalumab plus BCG had improved DFS.
On Feb. 18, 2026, investors weighed ImmunityBio’s EU bladder cancer win against its long slide since IPO and fresh legal ...
ANKTIVA plus BCG, with a 71% complete response rate, is the first immunotherapy to receive marketing authorization in Europe ...
The European Medicines Agency (EMA)’s Committee for Medicinal Products for Human Use (CHMP) has recommended granting a conditional marketing authorization in the EU for Anktiva to treat adults with ...
SUZHOU, China, Dec. 3, 2025 /PRNewswire/ -- On December 3, 2025 (local time in Arizona, USA), ImmVira Group ("ImmVira" or the "Company") announced a poster presentation at the 26th Annual Meeting of ...
Metachronous bladder recurrences after UTUC surgery may require more aggressive or different management than primary NMIBC. Bacillus Calmette Guérin (BCG) may be less effective in patients who develop ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results